Fate Therapeutics Inc
FATE1.240USD
0.000
Market hours （ET）Quotes delayed by 15 min
142.11MMarket Cap
LossP/E TTM
More Details of Fate Therapeutics Inc Company
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. Using its proprietary iPSC product platform, the Company has established a position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Its product candidates under development include FT819, FT522, FT829, FT825, FT836, and others. FT819 is its first iPSC-derived CAR T-cell product candidate. FT522 is its first iPSC-derived CAR NK cell product candidate that incorporates its novel Alloimmune Defense Receptor (ADR) technology.
Company Info
Ticker SymbolFATE
Company nameFate Therapeutics Inc
IPO dateOct 01, 2013
Founded at2007
CEODr. Bahram Valamehr, Ph.D.
Number of employees181
Security typeOrdinary Share
Fiscal year-endOct 01
Address12278 Scripps Summit Drive
CitySAN DIEGO
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code92131
Phone18588751803
Websitehttps://fatetherapeutics.com/
Ticker SymbolFATE
IPO dateOct 01, 2013
Founded at2007
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. William H. (Bill) Rastetter, Ph.D.
Dr. William H. (Bill) Rastetter, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
617.42K
--
Dr. John D. Mendlein, J.D., Ph.D.
Dr. John D. Mendlein, J.D., Ph.D.
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
311.23K
--
Dr. Bahram Valamehr, Ph.D.
Dr. Bahram Valamehr, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
80.08K
-70.04%
Ms. Cindy R. Tahl, J.D.
Ms. Cindy R. Tahl, J.D.
Chief Legal and Compliance Officer, Corporate Secretary
Chief Legal and Compliance Officer, Corporate Secretary
67.42K
-79.23%
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Director
Independent Director
11.33K
--
Dr. Shefali Agarwal, M.D.
Dr. Shefali Agarwal, M.D.
Independent Director
Independent Director
10.49K
--
Dr. Karin Jooss, Ph.D.
Dr. Karin Jooss, Ph.D.
Independent Director
Independent Director
9.85K
--
Dr. Xu Yuan, Ph.D.
Dr. Xu Yuan, Ph.D.
Independent Director
Independent Director
--
--
Mr. Michael Lee
Mr. Michael Lee
Independent Director
Independent Director
--
--
Dr. Neelufar (Neely) Mozaffarian, M.D., Ph.D.
Dr. Neelufar (Neely) Mozaffarian, M.D., Ph.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. William H. (Bill) Rastetter, Ph.D.
Dr. William H. (Bill) Rastetter, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
617.42K
--
Dr. John D. Mendlein, J.D., Ph.D.
Dr. John D. Mendlein, J.D., Ph.D.
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
311.23K
--
Dr. Bahram Valamehr, Ph.D.
Dr. Bahram Valamehr, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
80.08K
-70.04%
Ms. Cindy R. Tahl, J.D.
Ms. Cindy R. Tahl, J.D.
Chief Legal and Compliance Officer, Corporate Secretary
Chief Legal and Compliance Officer, Corporate Secretary
67.42K
-79.23%
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Director
Independent Director
11.33K
--
Dr. Shefali Agarwal, M.D.
Dr. Shefali Agarwal, M.D.
Independent Director
Independent Director
10.49K
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Thu, May 22
Updated: Thu, May 22
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Redmile Group, LLC
11.23%
ARK Investment Management LLC
9.00%
The Vanguard Group, Inc.
8.99%
BlackRock Institutional Trust Company, N.A.
7.32%
Schonfeld Strategic Advisors LLC
6.80%
Other
56.66%
Shareholders
Shareholders
Proportion
Redmile Group, LLC
11.23%
ARK Investment Management LLC
9.00%
The Vanguard Group, Inc.
8.99%
BlackRock Institutional Trust Company, N.A.
7.32%
Schonfeld Strategic Advisors LLC
6.80%
Other
56.66%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
37.69%
Investment Advisor
25.65%
Hedge Fund
18.92%
Research Firm
6.44%
Venture Capital
3.35%
Individual Investor
1.74%
Private Equity
1.47%
Bank and Trust
0.36%
Pension Fund
0.23%
Other
4.15%
Institutional Shareholding
Updated: Mon, Mar 3
Updated: Mon, Mar 3
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
439
113.58M
99.11%
-25.75M
2024Q4
487
105.43M
92.56%
-50.79M
2024Q3
521
119.20M
104.73%
-42.15M
2024Q2
531
125.64M
110.45%
-29.93M
2024Q1
543
126.44M
111.19%
-6.65M
2023Q4
556
99.29M
100.70%
-34.38M
2023Q3
581
100.01M
101.45%
-44.66M
2023Q2
611
113.36M
115.11%
-33.43M
2023Q1
624
117.20M
119.39%
-6.61M
2022Q4
637
109.94M
113.01%
-9.96M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Redmile Group, LLC
12.87M
11.23%
-296.11K
-2.25%
Dec 31, 2024
The Vanguard Group, Inc.
10.33M
9.02%
-47.55K
-0.46%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
8.49M
7.41%
+477.62K
+5.96%
Dec 31, 2024
Citadel Advisors LLC
4.38M
3.82%
+100.18K
+2.34%
Dec 31, 2024
Johnson & Johnson Innovation-JJDC, Inc.
3.38M
2.95%
--
--
Dec 31, 2024
Baker Bros. Advisors LP
3.26M
2.84%
+260.63K
+8.69%
Dec 31, 2024
Dimensional Fund Advisors, L.P.
2.90M
2.53%
+279.36K
+10.67%
Dec 31, 2024
View more
Related ETFs
Updated: Fri, Jun 6
Updated: Fri, Jun 6
Name
Proportion
Invesco NASDAQ Future Gen 200 ETF
0.66%
WisdomTree BioRevolution Fund
0.65%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
Global X Russell 2000 ETF
0.01%
ProShares Ultra Nasdaq Biotechnology
0.01%
ProShares UltraPro Russell2000
0.01%
Invesco Nasdaq Biotechnology ETF
0.01%
Proshares Ultra Russell 2000
0.01%
iShares Biotechnology ETF
0.01%
View more
Invesco NASDAQ Future Gen 200 ETF
Proportion0.66%
WisdomTree BioRevolution Fund
Proportion0.65%
ProShares Hedge Replication ETF
Proportion0.01%
iShares Russell 2000 Value ETF
Proportion0.01%
Global X Russell 2000 ETF
Proportion0.01%
ProShares Ultra Nasdaq Biotechnology
Proportion0.01%
ProShares UltraPro Russell2000
Proportion0.01%
Invesco Nasdaq Biotechnology ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
iShares Biotechnology ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
